<?xml version='1.0' encoding='utf-8'?>
<document id="27737931"><sentence text="Inhibition of Intestinal OATP2B1 by the Calcium Receptor Antagonist Ronacaleret Results in a Significant Drug-Drug Interaction by Causing a 2-Fold Decrease in Exposure of Rosuvastatin."><entity charOffset="40-47" id="DDI-PubMed.27737931.s1.e0" text="Calcium" /><entity charOffset="171-183" id="DDI-PubMed.27737931.s1.e1" text="Rosuvastatin" /><pair ddi="false" e1="DDI-PubMed.27737931.s1.e0" e2="DDI-PubMed.27737931.s1.e0" /><pair ddi="false" e1="DDI-PubMed.27737931.s1.e0" e2="DDI-PubMed.27737931.s1.e1" /></sentence><sentence text="Rosuvastatin is a widely prescribed antihyperlipidemic which undergoes limited metabolism, but is an in vitro substrate of multiple transporters [organic anion transporting polypeptide 1B1 (OATP1B1), OATP1B3, OATP1A2, OATP2B1, sodium-taurocholate cotransporting polypeptide, breast cancer resistance protein (BCRP), multidrug resistance protein 2 (MRP2), MRP4, organic anion transporter 3]"><entity charOffset="0-12" id="DDI-PubMed.27737931.s2.e0" text="Rosuvastatin" /><entity charOffset="218-225" id="DDI-PubMed.27737931.s2.e1" text="OATP2B1" /><pair ddi="false" e1="DDI-PubMed.27737931.s2.e0" e2="DDI-PubMed.27737931.s2.e0" /><pair ddi="false" e1="DDI-PubMed.27737931.s2.e0" e2="DDI-PubMed.27737931.s2.e1" /></sentence><sentence text=" It is therefore frequently used as a probe substrate in clinical drug-drug interaction (DDI) studies to investigate transporter inhibition" /><sentence text=" Although each of these transporters is believed to play a role in rosuvastatin disposition, multiple pharmacogenetic studies confirm that OATP1B1 and BCRP play an important role in vivo"><entity charOffset="67-79" id="DDI-PubMed.27737931.s4.e0" text="rosuvastatin" /></sentence><sentence text=" Ronacaleret, a drug-development candidate for treatment of osteoporosis (now terminated), was shown to inhibit OATP1B1 in vitro (IC50 = 11 µM), whereas it did not inhibit BCRP" /><sentence text=" Since a DDI risk through inhibition of OATP1B1 could not be discharged, a clinical DDI study was performed with rosuvastatin before initiation of phase II trials"><entity charOffset="113-125" id="DDI-PubMed.27737931.s6.e0" text="rosuvastatin" /></sentence><sentence text=" Unexpectedly, coadministration with ronacaleret decreased rosuvastatin exposure by approximately 50%, whereas time of maximal plasma concentration and terminal half-life remained unchanged, suggesting decreased absorption and/or enhanced first-pass elimination of rosuvastatin"><entity charOffset="59-71" id="DDI-PubMed.27737931.s7.e0" text="rosuvastatin" /><entity charOffset="265-277" id="DDI-PubMed.27737931.s7.e1" text="rosuvastatin" /><pair ddi="false" e1="DDI-PubMed.27737931.s7.e0" e2="DDI-PubMed.27737931.s7.e0" /><pair ddi="false" e1="DDI-PubMed.27737931.s7.e0" e2="DDI-PubMed.27737931.s7.e1" /></sentence><sentence text=" Of the potential in vivo rosuvastatin transporter pathways, two might explain the observed results: intestinal OATP2B1 and hepatic MRP4"><entity charOffset="26-38" id="DDI-PubMed.27737931.s8.e0" text="rosuvastatin" /></sentence><sentence text=" Further investigations revealed that ronacaleret inhibited OATP2B1 (in vitro IC50 = 12 µM), indicating a DDI risk through inhibition of absorption" /><sentence text=" Ronacaleret did not inhibit MRP4, discharging the possibility of enhanced first-pass elimination of rosuvastatin (reduced basolateral secretion from hepatocytes into blood)"><entity charOffset="101-113" id="DDI-PubMed.27737931.s10.e0" text="rosuvastatin" /></sentence><sentence text=" Therefore, a likely mechanism of the observed DDI is inhibition of intestinal OATP2B1, demonstrating the in vivo importance of this transporter in rosuvastatin absorption in humans"><entity charOffset="148-160" id="DDI-PubMed.27737931.s11.e0" text="rosuvastatin" /></sentence><sentence text="" /></document>